Last reviewed on RxList: 1/28/2021
Zemuron Side Effects Center

What Is Zemuron?

Zemuron (rocuronium bromide) is a nondepolarizing neuromuscular blocking agent given before general anesthesia in preparation for surgery. Zemuron helps keep the body still during surgery and also relaxes the throat so a breathing tube can be more easily inserted before surgery. Zemuron is available in generic form.

What Are Side Effects of Zemuron?

Common side effects of Zemuron include:

Dosage for Zemuron

Zemuron is only administered by clinicians experienced with the use, actions, characteristics and complications of neuromuscular blocking agents. Doses of Zemuron injection are individualized based on the condition being treated and the patient's weight, among other factors.

What Drugs, Substances, or Supplements Interact with Zemuron?

Zemuron may interact with lithium, procainamide, seizure medication, antacids or mineral supplements containing magnesium, steroids, or antibiotics. Tell your doctor all medications and supplements you use.

Zemuron During Pregnancy and Breastfeeding

During pregnancy, Zemuron should only be used if prescribed. It is unknown if this medication passes into breast milk or if it could harm a nursing baby. Consult your doctor before breastfeeding.

Additional Information

Our Zemuron (rocuronium bromide) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


Digestive Disorders: Common Misconceptions See Slideshow
Zemuron Consumer Information

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

You will remain under constant supervision during treatment with rocuronium. Your caregivers will watch for any serious side effects. Tell your caregivers right away if you have:

  • ongoing muscle weakness; or
  • loss of movement in any part of your body (especially in adults who are 65 and older).

Common side effects may include:

  • a light-headed feeling, like you might pass out; or
  • high blood pressure (severe headache, blurred vision, pounding in your neck or ears, anxiety, confusion).

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Zemuron (Rocuronium Bromide Injection)


About how much does an adult human brain weigh? See Answer
Zemuron Professional Information


In clinical trials, the most common adverse reactions (2%) are transient hypotension and hypertension.

The following adverse reactions are described, or described in greater detail, in other sections:

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Clinical studies in the US (n=1137) and Europe (n=1394) totaled 2531 patients. The patients exposed in the US clinical studies provide the basis for calculation of adverse reaction rates. The following adverse reactions were reported in patients administered ZEMURON (all events judged by investigators during the clinical trials to have a possible causal relationship):

Adverse reactions in greater than 1% of patients: None

Adverse reactions in less than 1% of patients (probably related or relationship unknown):

Cardiovascular: arrhythmia, abnormal electrocardiogram, tachycardia

Digestive: nausea, vomiting

Respiratory: asthma (bronchospasm, wheezing, or rhonchi), hiccup

Skin and Appendages: rash, injection site edema, pruritus

In the European studies, the most commonly reported reactions were transient hypotension (2%) and hypertension (2%); these are in greater frequency than the US studies (0.1% and 0.1%). Changes in heart rate and blood pressure were defined differently from in the US studies in which changes in cardiovascular parameters were not considered as adverse events unless judged by the investigator as unexpected, clinically significant, or thought to be histamine related.

In a clinical study in patients with clinically significant cardiovascular disease undergoing coronary artery bypass graft, hypertension and tachycardia were reported in some patients, but these occurrences were less frequent in patients receiving beta or calcium channel-blocking drugs. In some patients, ZEMURON was associated with transient increases (30% or greater) in pulmonary vascular resistance. In another clinical study of patients undergoing abdominal aortic surgery, transient increases (30% or greater) in pulmonary vascular resistance were observed in about 24% of patients receiving ZEMURON 0.6 or 0.9 mg/kg.

In pediatric patient studies worldwide (n=704), tachycardia occurred at an incidence of 5.3% (n=37), and it was judged by the investigator as related in 10 cases (1.4%).

Postmarketing Experience

The following adverse reactions have been identified during post-approval use of ZEMURON. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Immune System Disorders

In clinical practice, there have been reports of severe allergic reactions (anaphylactic and anaphylactoid reactions and shock) with ZEMURON, including some that have been life-threatening and fatal [see WARNINGS AND PRECAUTIONS].

General Disorders And Administration Site Conditions

There have been reports of malignant hyperthermia with the use of ZEMURON [see WARNINGS AND PRECAUTIONS].

Read the entire FDA prescribing information for Zemuron (Rocuronium Bromide Injection)

© Zemuron Patient Information is supplied by Cerner Multum, Inc. and Zemuron Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors